Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism.
Weinhäuser I, Pereira-Martins DA, Almeida LY, Hilberink JR, Silveira DRA, Quek L, Ortiz C, Araujo CL, Bianco TM, Lucena-Araujo A, Mota JM, Hogeling SM, Sternadt D, Visser N, Diepstra A, Ammatuna E, Huls G, Rego EM, Schuringa JJ. Weinhäuser I, et al. Among authors: quek l. Sci Adv. 2023 Apr 14;9(15):eadf8522. doi: 10.1126/sciadv.adf8522. Epub 2023 Apr 14. Sci Adv. 2023. PMID: 37058562 Free article.
Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis.
Bezerra MF, Lima AS, Piqué-Borràs MR, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, Weinhäuser I, Franca-Neto PL, Quek L, Corby A, Oliveira MM, Lima MM, de Assis RA, de Melo Campos P, Duarte BK, Bendit I, Rocha V, Rego EM, Traina F, Saad ST, Beltrão EI, Bezerra MA, Lucena-Araujo AR. Bezerra MF, et al. Among authors: quek l. Blood. 2020 Mar 12;135(11):870-875. doi: 10.1182/blood.2019003339. Blood. 2020. PMID: 31977039 Free article. No abstract available.
Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia.
Silveira DRA, Quek L, Santos IS, Corby A, Coelho-Silva JL, Pereira-Martins DA, Vallance G, Brown B, Nardinelli L, Silva WF, Velloso EDRP, Lucena-Araujo AR, Traina F, Peniket A, Vyas P, Rego EM, Bendit I, Rocha V. Silveira DRA, et al. Among authors: quek l. Blood Adv. 2020 May 26;4(10):2339-2350. doi: 10.1182/bloodadvances.2019001419. Blood Adv. 2020. PMID: 32453839 Free PMC article.
A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?
Silveira DRA, Coelho-Silva JL, Silva WF, Vallance G, Pereira-Martins DA, Madeira MIA, Figueredo-Pontes LL, Velloso EDRP, Simões BP, Peniket A, Danby R, Rego EM, Vyas P, Traina F, Bendit I, Quek L, Rocha V. Silveira DRA, et al. Among authors: quek l. Leuk Lymphoma. 2021 Jan;62(1):147-157. doi: 10.1080/10428194.2020.1827252. Epub 2020 Sep 30. Leuk Lymphoma. 2021. PMID: 32996373
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.
Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, Lau IJ, Doondeea J, Usukhbayar B, Kennedy A, Metzner M, Goardon N, Ivey A, Allen C, Gale R, Davies B, Sternberg A, Killick S, Hunter H, Cahalin P, Price A, Carr A, Griffiths M, Virgo P, Mackinnon S, Grimwade D, Freeman S, Russell N, Craddock C, Mead A, Peniket A, Porcher C, Vyas P. Quek L, et al. J Exp Med. 2016 Jul 25;213(8):1513-35. doi: 10.1084/jem.20151775. Epub 2016 Jul 4. J Exp Med. 2016. PMID: 27377587 Free PMC article. Clinical Trial.
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P. Quek L, et al. Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16. Nat Med. 2018. PMID: 30013198 Free PMC article.
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Watts JM, Pollyea DA, Fathi AT, Tallman MS, Kantarjian HM, Stone RM, Quek L, Konteatis Z, Dang L, Nicolay B, Nejad P, Liu G, Zhang V, Liu H, Goldwasser M, Liu W, Marks K, Bowden C, Biller SA, Attar EC, Wu B. Choe S, et al. Among authors: quek l. Blood Adv. 2020 May 12;4(9):1894-1905. doi: 10.1182/bloodadvances.2020001503. Blood Adv. 2020. PMID: 32380538 Free PMC article.
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P. Craddock CF, et al. Among authors: quek ls. Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765326 Clinical Trial.
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B, Farnoud NR, de Botton S, Bernard OA, Wu B, Yen KE, Tallman MS, Papaemmanuil E, Penard-Lacronique V, Thakurta A, Vyas P, Levine RL. Amatangelo MD, et al. Among authors: quek l. Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6. Blood. 2017. PMID: 28588019 Free PMC article. Clinical Trial.
175 results